Jeremy M. Shefner

Jeremy M. Shefner

Auto-generated profile, based on publicly available information

Jeremy M. Shefner

Barrow Neurological Institute and Creighton University Phoenix Arizona USA

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Clinical Neurophysiology
Verified
Journal Article
Open access
JSJeremy M. Shefner
Jeremy M. Shefner
AAAmmar Al-Chalabi
Ammar Al-Chalabi
MBMark Baker
Mark Baker
LCLi-Ying Cui
Li-Ying Cui
MCMamede de Carvalho
Mamede de Carvalho
MKMatthew C. Kiernan
Matthew C. Kiernan

18 December 2020 in Nature Reviews Neurology
Verified
Journal Article
Closed access
PDF file
MKMatthew Colm Kiernan
Matthew Colm Kiernan
SVSteve Vucic
Steve Vucic
KTKevin Talbot
Kevin Talbot
CMChristopher J. McDermott
Christopher J. McDermott
OHOrla Hardiman
Orla Hardiman
MTMartin R. Turner
Martin R. Turner

14 March 2023 in Neurology
Verified
Journal Article
Open access
PDF file
DRDaniel B. Rubin
Daniel B. Rubin
AAA. Bolu Ajiboye
A. Bolu Ajiboye
LBLaurie Barefoot
Laurie Barefoot
MBMarguerite Bowker
Marguerite Bowker
SCSydney S. Cash
Sydney S. Cash
LHLeigh R. Hochberg
Leigh R. Hochberg
Background and Objectives Brain-computer interfaces (BCIs) are being developed to restore mobility, communication, and functional independence to people with paralysis. Though supported by decades of preclinical data, the safety of chronically implanted microelectrode array BCIs in humans is unknown. We report safety results from the prospective, open-label, nonrandomized BrainGate feasibility study (NCT00912041), the largest and longest-running clinical trial of an implanted BCI. Methods Adults aged 18–75 years with quadriparesis from spinal cord injury, brainstem stroke, or motor neuron disease were enrolled through 7 clinical sites in the United States. Participants underwent surgical implantation of 1 or 2 microelectrode arrays in the motor cortex of the dominant cerebral hemisphere. The primary safety outcome was device-related serious adverse events (SAEs) requiring device explantation or resulting in death or permanently increased disability during the 1-year postimplant evaluation period. The secondary outcomes included the type and frequency of other adverse events and the feasibility of the BrainGate system for controlling a computer or other assistive technologies. Results From 2004 to 2021, 14 adults enrolled in the BrainGate trial had devices surgically implanted. The average duration of device implantation was 872 days, yielding 12,203 days of safety experience. There were 68 device-related adverse events, including 6 device-related SAEs. The most common device-related adverse event was skin irritation around the percutaneous pedestal. There were no safety events that required device explantation, no unanticipated adverse device events, no intracranial infections, and no participant deaths or adverse events resulting in permanently increased disability related to the investigational device. Discussion The BrainGate Neural Interface system has a safety record comparable with other chronically implanted medical devices. Given rapid recent advances in this technology and continued performance gains, these data suggest a favorable risk/benefit ratio in appropriately selected individuals to support ongoing research and development. Trial Registration Information ClinicalTrials.gov Identifier: NCT00912041. Classification of Evidence This study provides Class IV evidence that the neurosurgically placed BrainGate Neural Interface system is associated with a low rate of SAEs defined as those requiring device explantation, resulting in death, or resulting in permanently increased disability during the 1-year postimplant period.

24 September 2020 in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Verified
Journal Article
Open access
JSJeremy M. Shefner
Jeremy M. Shefner
JAJinsy A. Andrews
Jinsy A. Andrews
AGAngela Genge
Angela Genge
CJCarlayne Jackson
Carlayne Jackson
NLNoah Lechtzin
Noah Lechtzin
SRStacy A. Rudnicki
Stacy A. Rudnicki
To evaluate safety, dose response, and preliminary efficacy of reldesemtiv over 12 weeks in patients with amyotrophic lateral sclerosis (ALS). Methods: Patients (≤2 years since diagnosis) with slow...

9 August 2016 in Neurology
Verified
Journal Article
Closed access
PDF file
JSJeremy M. Shefner
Jeremy M. Shefner
DLDawei Liu
Dawei Liu
MLMelanie L. Leitner
Melanie L. Leitner
DSDavid Schoenfeld
David Schoenfeld
DJDonald R. Johns
Donald R. Johns
MCMerit Cudkowicz
Merit Cudkowicz
Objective: To study the attributes of quantitative strength testing using hand-held dynamometry (HHD) as an efficacy measure in 2 large phase 3 amyotrophic lateral sclerosis (ALS) trials. Methods: In the phase 3 trials of ceftriaxone and dexpramipexole, 513 and 943 patients, respectively, were enrolled in double-blind, randomized, placebo-controlled trials with planned follow-up of at least 1 year. Patients were studied every 3 months in the ceftriaxone study and every 2 months in the dexpramipexole study. Evaluators of HHD were trained and had to show evidence of adequate performance of strength testing; the testing paradigm involved testing 9 muscle groups in the upper and lower extremity bilaterally. Neither drug significantly affected any outcome measure. Strength measurements were evaluated by individual muscle and by megascores, which averaged scaled strength measures to produce an overall measure of muscle strength. Results: A measure combining rate of decline with both within- and between-patient variabilities of measurement, the coefficient of variation for rate of change, was calculated, and showed that HHD overall performed slightly less well than Amyotrophic Lateral Sclerosis Functional Rating Scale–revised (ALSFRS-R) but better than vital capacity. Individual muscles were highly correlated to the identical muscles on the contralateral side, as well as to other muscles in the same body region. Strength decline was correlated both with ALSFRS-R and vital capacity. Conclusion: Quantitative strength testing using HHD is a reliable and reproducible measure of decline in ALS.

13 May 2019 in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Verified
Journal Article
Open access
JSJeremy M. Shefner
Jeremy M. Shefner
MCMerit E. Cudkowicz
Merit E. Cudkowicz
OHOrla Hardiman
Orla Hardiman
BCBettina M. Cockroft
Bettina M. Cockroft
JLJacqueline H. Lee
Jacqueline H. Lee
OGon behalf of the VITALITY-ALS STUDY GROUP
on behalf of the VITALITY-ALS STUDY GROUP
Objective: To assess the efficacy of tirasemtiv, a fast skeletal muscle troponin activator, vs. placebo in patients with amyotrophic lateral sclerosis. Methods: VITALITY-ALS (NCT02496767) was a multinational, double-blind, randomized, placebo-controlled clinical trial. Participants tolerating 2 weeks of open-label tirasemtiv (125 mg twice daily) were randomized 3:2:2:2 to placebo or one of three target tirasemtiv dose levels, using an escalating dosage protocol lasting 28 days. The primary outcome measure was changed in slow vital capacity (SVC) at 24 weeks. Secondary endpoints included a change in muscle strength and time to respiratory milestones of disease progression. Results: Of 744 participants, 565 tolerated open-label tirasemtiv and received randomized treatment. By 24 weeks, 23 (12.2%) placebo-treated participants discontinued study treatment vs. 129 (34.2%) randomized to tirasemtiv. SVC declined by 14.4% (95% CI: −16.8, −11.9) in the placebo group and 13.4% (95% CI: −15.3, −11.6) in the tirasemtiv group (p = 0.56). Secondary endpoints did not show significant differences. However, participants who tolerated tirasemtiv at their randomized dose showed a numeric trend toward a dose-related slowing of decline in SVC (p = 0.11). Dizziness, fatigue, nausea, weight loss, and insomnia occurred more frequently on tirasemtiv. Serious adverse events were similar across groups. Conclusions: Tirasemtiv did not alter the decline of SVC or significantly impact secondary outcome measures. Poor tolerability of tirasemtiv may have contributed to this result. However, participants tolerating their intended dose exhibited a trend toward treatment benefit on SVC, suggesting the underlying mechanism of action may still hold promise, as is being tested with a different fast skeletal muscle troponin activator (NCT03160898).